Literature DB >> 9013892

Association of aminopeptidase N and endopeptidase 24.15 inhibitors potentiate behavioral effects mediated by nociceptin/orphanin FQ in mice.

F Noble1, B P Roques.   

Abstract

The behavioral effects induced by central administration in mice of the endogenous ORL1 (opioid receptor-like1) ligand, nociceptin/orphanin FQ, were investigated in the absence or presence of inhibitors of aminopeptidase N (bestatin) and endopeptidase 24.15 (Z-(L,D)Phe psi(PO2CH2)(L,D)Ala-Arg-Phe) recently shown to be involved in the metabolism of the heptadecapeptide in vitro. A severe reduction in motor activity induced by nociceptin/orphanin FQ was measured in two tests (spontaneous motor activity and open field). This pharmacological effect was shown to be potentiated by the association of bestatin and Z-(L,D)Phe psi(PO2CH2)(L,D)Ala-Arg-Phe, confirming in vivo the involvement of these peptidases in nociceptin/orphanin FQ inactivation. In our conditions, these inhibitors were devoid of intrinsic effects, suggesting a low tonic regulation by the heptadecapeptide of the measured behaviour.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9013892     DOI: 10.1016/s0014-5793(96)01476-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  [Nphe(1)]-Nociceptin (1-13)-NH(2), a nociceptin receptor antagonist, reverses nociceptin-induced spatial memory impairments in the Morris water maze task in rats.

Authors:  J P Redrobe; G Calo; R Guerrini; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  CD13/APN is activated by angiogenic signals and is essential for capillary tube formation.

Authors:  S V Bhagwat; J Lahdenranta; R Giordano; W Arap; R Pasqualini; L H Shapiro
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

Review 3.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

4.  [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.

Authors:  Girolamo Calo; Anna Rizzi; Daniela Rizzi; Raffaella Bigoni; Remo Guerrini; Giuliano Marzola; Matteo Marti; John McDonald; Michele Morari; David G Lambert; Severo Salvadori; Domenico Regoli
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

5.  Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice.

Authors:  Anna Rizzi; Daniela Rizzi; Giuliano Marzola; Domenico Regoli; Bjarne Due Larsen; Jorgen Soberg Petersen; Girolamo Calo'
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

6.  First discrete autoradiographic distribution of aminopeptidase N in various structures of rat brain and spinal cord using the selective iodinated inhibitor [125I]RB 129.

Authors:  F Noble; G Banisadr; F Jardinaud; T Popovici; R Lai-Kuen; H Chen; L Bischoff; S M Parsadaniantz; M C Fournie-Zaluski; B P Roques
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

Review 7.  A systematic review of the role of the nociceptin receptor system in stress, cognition, and reward: relevance to schizophrenia.

Authors:  Muhammad Saad Khan; Isabelle Boileau; Nathan Kolla; Romina Mizrahi
Journal:  Transl Psychiatry       Date:  2018-02-02       Impact factor: 6.222

Review 8.  The moonlighting enzyme CD13: old and new functions to target.

Authors:  Paola Mina-Osorio
Journal:  Trends Mol Med       Date:  2008-07-05       Impact factor: 11.951

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.